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 PApo-10'-lycopenoic acid (apo-10-lycac), a metabolite of lycopene, has been shown to possess potent biologicalactivities, notably via the retinoic acid receptors (RAR). In the current study, its impact on adipose tissue and
adipocytes was studied. In microarray experiments, the set of genes regulated by apo-10-lycac treatments was
compared to the set of genes regulated by all-trans retinoic acid (ATRA), the natural ligand of RAR, in adipocytes.
Approximately 27.5% of the genes regulated by apo-10-lycac treatmentswere also regulated byATRA, suggesting
a common ability in terms of gene expression modulation, possibly via RAR transactivation. The physiological
impact of apo-10-lycac on adipose tissue biology was evaluated. If it had no effect on adipogenesis in the 3T3-
L1 cell model, this metabolite may have a preventative effect against inﬂammation, by preventing the increase
in the inﬂammatory markers, interleukin 6 and interleukin 1β in various dedicated models. The ability of apo-
10-lycac to transactivate the RAR and to modulate the transcription of RAR target gene was brought in vivo in
adipose tissue. While apo-10-lycac was not detected in adipose tissue, a metabolite with a molecular weight
with 2 Da larger mass was detected, suggesting that a dihydro-apo-10'-lycopenoic acid, may be present in
adipose tissue and that this compound could active or may lead to further active RAR-activating apo-10-lycac
metabolites. Since apo-10-lycac treatments induce anti-inﬂammatory effects in adipose tissue but do not inhibit
adipogenesis, we propose that apo-10-lycac treatments and its potential active metabolites in WAT may be
considered for prevention strategies relevant for obesity-associated pathologies.R
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O1. Introduction
Lycopene is a carotenoid found in multiple vegetables and fruits,
such as tomato and tomato-based products, papaya, and watermelon
[1]. Its beneﬁcial health effects have been studied extensively, especially
in the prevention of prostate cancer where it has been demonstrated to
be a potential chemoprotective agent [2,3]. Several studies suggest that
lycopene has an impact on adipose tissuemetabolism. First, lycopene is
the predominant carotenoid in human adipose tissue [4]. Second, it has67
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74
75recently been reported that a higher intake of lycopene was associated
with a smaller waist circumference and lower visceral and subcutane-
ous fat mass [5]. Third, we demonstrated that lycopene inhibited proin-
ﬂammatory cytokine and chemokine expression in adipose tissue [6].
Finally, it has beenﬁrmly established that the concentration of lycopene
in adipose tissue is correlated to a reduction in the risk of developing a
cardiovascular disease in men [7]. Such beneﬁcial effects of lycopene
might be due to its positive effects on adipose tissue. Indeed adipose
tissue has a well-established role in the genesis of obesity-associated
pathologies, such as insulin resistance and type II diabetes, which are
risk factors for cardiovascular diseases.
The metabolism of lycopene remains unclear. After intestinal
absorption, which is mediated, at least in part, by SR-B1 [8], lycopene
is incorporated into chylomicrons and released into the lymphatic sys-
tem for transport to the liver [1]. In the plasma, lycopene is transported
in LDL and VLDL for distribution to multiple organs. Our group recently
demonstrated that CD36 is involved in the uptake of lycopene by
adipose tissue and adipocytes [9]. In various organs in ferrets andsue biology via the retinoic acid receptors, Biochim.
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mice, lycopene can be metabolized by β-carotene 9',10'-dioxygenase
(BCDO2) [10,11]. This enzyme is responsible for the eccentric cleavage
of lycopene (especially the cis-lycopene isomers). Indeed, Hu et al.
[10] demonstrated that the cis isomer of lycopene was metabolized
into apo-10'-lycopenal by ferret BCDO2 in vitro, and that all-trans lyco-
pene supplementation in these animals resulted in the formation of
apo-10'-lycopenol in the lung. They also demonstrated that apo-10'-
lycopenal can be metabolized into apo-10'-lycopenoic acid (apo-10-
lycac) or apo-10'-lycopenol, depending on whether NAD+ or NADH
are present as cofactors. Several other lycopene metabolites were
identiﬁed in rat liver (apo-8'-lycopenal and apo-12'-lycopenal [12]).
Apo-lycopenals were recently detected in human plasma, possibly
derived from ingested tomato products or from lycopene in vivometab-
olism [13].
Among thesemetabolites, the apo-10-lycac has been shown to be an
activemetabolite, especially in cancer cells. Indeed, Lian et al. [14] dem-
onstrated that treatment of human bronchial epithelial cells with
apo-10-lycac resulted in the nuclear accumulation of Nrf2, which is
associated with an induction of phase II detoxifying/antioxidant en-
zymes [14]. This group previously reported that apo-10-lycac transacti-
vated the retinoic acid receptor β (RARβ) promoter in relatively high
concentrations (N3 μM), and induced the expression of RARβ in bron-
chial and lung cancer cells in vitro[15]. These data strongly suggest
that apo-10-lycac is highly active in terms of the regulation of gene
expression in organs that have an optimal environment for further
potential bioactivation to active metabolites.
Interestingly, BCDO2 is highly expressed in adipose tissue [16].
Thus, we hypothesized that the apo-10-lycac and/or other related
bioactive derivatives are generated in adipose tissue and have the
ability to impact on adipose tissue biology via the transactivation of
RAR. In the current study, we evaluated its effects on the transcrip-
tome of adipocytes, as well as on different aspects of adipose tissue
biology, including adipogenesis and prevention of inﬂammation. We
also demonstrated that apo-10-lycac treatments induce potent RAR
activation in vivo and in vitro. We conclude that this metabolite affects
adipose tissue and adipocyte biology in a manner similar to all-trans
retinoic acid (ATRA), a well-known natural ligand of RAR.
2. Materials and methods
2.1. Chemicals
Apo-10'-lycopenoic acid (apo-10-lycac) was obtained by organic
synthesis as described by Reynaud et al. [17].
2.2. Animal experiments
For ex vivo experiments, the care and use ofmicewere in accordance
with French guidelines and approved by the local experimental animals
ethics committee. Adult male C57BL/6j mice were housed in a temper-
ature-, humidity- and light-controlled room. Mice were fed a standard
chow diet and water ad libitum. Mice on a high-fat diet (n=6) were
fed a diet containing 35% fat for 6 weeks, as described previously [18].
For in vivo RAR transactivation experiments, RARE-luc mice (Cgene
AS, Olso, Norway) were engineered to express the ﬁreﬂy luciferase
gene under the control of RARE (retinoic acid response element) [19].
The animalswere housed in standard plastic cages at room temperature
(20±2 °C) according to the Hungarian guidelines for the care and use
of animals. They had ad libitum access to both food and water. Standard
laboratory animal diet (Altromin, VRF 1)was acquired from Charles River
(Budapest, H). Male mice (10–12weeks old) were used. In each group,
4–6 animals were analyzed.
For HPLC analysis, six C57BL/6 male mice were used. Three animals
were injected intravenously with lycopene (50 mg/kg body weight),
and three animals were treated with vehicle. After 4 h, animals werePlease cite this article as: E. Gouranton, et al., Apo-10'-lycopenoic acid im
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sacriﬁced by anesthesia with halothane. Spleens were collected and
snap-frozen in liquid nitrogen for HPLC analysis.
2.3. Ex vivo culture of adipose tissue explants
Adipose tissue explants ofmicewere recovered, rinsed in saline buffer
and placed in DMEM supplemented with 10% FBS at 37 °C in a 5% CO2
humidiﬁed atmosphere. The medium was changed after 1, 3 and 24 h.
Explants of adipose tissues from mice who consumed a high-fat diet or
normal chow as a control were treated with apo-10-lycac (2 μM) for
24 h. Adipose tissues of mice fed normal chow were cultured for 24 h
with apo-10-lycac, followed by a TNFα stimulation (15 ng/ml; 3 h).
2.4. Bioluminescence imaging and quantiﬁcation
An Andor IQ imaging system (Belfast, IRL), which consists of an
Andor-ixon cooled charged coupled device (CCD) camera, housed in a
Unit-one (Birkerod, DK) black box and connected to a computer system,
was used for data acquisition and analysis. Groups of 10- to 12-week-
old male mice were treated with apo-10-lycac (4 mg/kg body weight),
ATRA (50 mg/kg body weight) or DMSO by oral gavage 16 h before
screening. Reporter animals received 120 mg/kg D-luciferin (Promega)
intra-peritoneally. Mice were euthanized by cervical dislocation
15min later. Subsequently, organs were rapidly excised and placed
under a CCD camera. Organs were kept at−80 °C for later HPLC analy-
sis. Bioluminescence images were taken using a 5-min integration time.
The photon signals were quantiﬁed by the Andor IQ 1.6. program.
Luciferase expression was determined as the integrated intensity/area.
Data are presented as the means±SEM values of 4–6 different animals
per treatment group.
2.5. Cell culture
3T3-L1 preadipocytes (ATCC, Manassas, VA, USA) were seeded in
dishes with a 3.5-cm diameter at a density of 15×104 cells/well. Cells
were grown in DMEM supplemented with 10% FBS at 37 °C in a 5%
CO2 humidiﬁed atmosphere, as reported previously [20]. To induce
differentiation, 2-day post-conﬂuent 3T3-L1 preadipocytes (day 0)
were stimulated for 48 h with 0.5 mM isobutylmethylxanthine,
0.25 μmol/L dexamethasone, and 1 μg/ml insulin in DMEM supplemen-
ted with 10% FBS. Cells were then maintained in DMEM supplemented
with 10% FBS and 1 μg/ml insulin. In order to examine the effect of
apo-10-lycac and ATRA on gene expression, 3T3-L1 adipocyteswere in-
cubatedwith 2 μMapo-10-lycac or ATRA for 24 h, as reported previous-
ly [21]. To examine the effect of apo-10-lycac on adipocyte
differentiation, 2-day post-conﬂuent 3T3-L1 preadipocytes received
2 μMapo-10-lycac or ATRA every 2 days until the end of the experiment
at day 9. The data are presented as the mean of three independent
experiments, each performed in triplicate. To examine the anti-inﬂam-
matory effect of apo-10-lycac and ATRA, 3T3-L1 adipocytes were incu-
bated with molecules (2 μM) for 24 h. These adipocytes were then
incubatedwith TNFα (15 ng/ml) for 3 h. All treatmentswere performed
on day 8. Human preadipocytes were purchased from Promocell
(Heidelberg, D) and cultured following the company's instructions.
Mature adipocytes (day 14) were incubated with apo-10-lycac (2 μM,
24 h) followed by an incubation with TNFα (15 ng/ml) for 3 h.
2.6. RAR transactivation assay in vitro
The reporter plasmid containing the gene for luciferase under the
control of four copies of the Gal4 binding site UAS was transfected in
3T3-L1 cells, together with plasmids CMX-Gal4 or CMX-Gal4-hRARa
(generous gift of Dr. Makishima; Nihon University School of Medicine,
Tokyo). The transfection was performed using Lipofectamine 2000
(Invitrogen). After overnight incubation with the transfection mixes,
the medium was replaced by DMEM supplemented with 10% FBS andpacts adipose tissue biology via the retinoic acid receptors, Biochim.
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3E. Gouranton et al. / Biochimica et Biophysica Acta xxx (2011) xxx–xxxvarious concentration of apo-10-lycac or ATRA. The cells were treated
for 24 h. The cells were lysed and assayed for luciferase activity using
a luciferase assay system (Promega, Madison, WI), which was normal-
ized to β-galactosidase activity as previously described [6]. The trans-
fection experiments were performed in triplicate and repeated three
times independently.
2.7. RNA isolation and qPCR
Total cellular RNAwas extracted from 3T3-L1 cells and mice epidid-
ymal fat pads using TRIzol reagent according to the manufacturer's
instructions. cDNA was synthesized from 1 μg of total RNA in 20 μl
using random primers and Moloney murine leukemia virus reverse
transcriptase. Real Time Quantitative RT-PCR analyses for the genes
were performed using theMx3005P Real-Time PCR System (Stratagene,
La Jolla, CA, USA) as described previously [22]. For each condition,
expression was quantiﬁed in duplicate, and 18S mRNA was used as
the endogenous control in the comparative cycle threshold (CT)
method.
2.8. Hybridization arrays and microarray data analysis
RNA quality control was performed on an Agilent 2100 Bioanalyzer
(Massy, F)with 6000NanoChips according to themanufacturer's instruc-
tions andas reportedpreviously [23]. RNA from three independent exper-
iments were pooled per treated group and hybridized to Agilent WholeU
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45225 123ATRA Apo-10-lycac
A BUpregulated genes
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Fig. 1. Comparison of genes regulated by apo-10’-lycopenoic acid and ATRA in 3T3-L1 adipocyte
regulated genes in 3T3-L1 adipocytes due to apo-10'-lycopenoic acid treatment in comparison
3T3-L1 adipocytes were incubated with apo-10’-lycopenoic acid (2 μM) or ATRA (2 μM) for 24
computed using Genespring GX10. B. Filtered fold change (fold change of 1.5) of commonly r
were plotted. The correlation line was drawn, and the Pearson correlation coefﬁcient and the
ﬁltered data using PermutMatrix. Apo-10’-lycopenoic acid is abbreviated as apo-10-lycac.
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Human Genome (4x44k; Massy, F). All labeling, hybridization, washing
and scanning were performed as described in the manufacturer's proto-
col. Arrays were scanned with an Agilent Scanner (Massy, F). Data were
extracted with Agilent Feature Extraction v9.5.3 and analyzed with Agi-
lent GeneSpring GX v10.0 (Massy, F). Data were determined to be signif-
icant based on P-value (Pb0.05) and fold change (1.5 or not). Pathway
analyses were performed using Metacore (http://www.genego.com/
metacore.php). A scatter plot was generated, and the associated correla-
tion analysiswas performedwith SPSS 17. Creation of a heatmapwasper-
formed with PermutMatrix [24].
2.9. HPLC MS-MS determinations
We used an existing high performance liquid chromatography/
mass spectrometry / mass spectrometry (HPLC MS-MS) conﬁguration
similar to that already published [25], except a novel andmore sensitive
mass spectrometer was used (Micromass Quattro Ultima PT, Manches-
ter, UK; donated by Biosystems Int., Evry, F). The separation using HPLC
was performed in amanner similar towhat has been reportedprevious-
ly [25]. For the detection of apo-10-lycac, we established a speciﬁc
MS-MSmethod usingAPCI (+) settingwith 393 to N269m/z, a collision
energy of 10 V, a dwell time 0.3 s and a cone voltage of 50 V as param-
eters for multiple reaction monitoring (MRM) measurements. Detec-
tion of lycopene metabolites with a molecular weight of 395 Da was
performed using a single ion recording (SIR) setting at 395 m/z and a
photodiodearray detector (Waters 996, Waters KFT., Budapest, H)
placed in series before the MS detector.E
D
 
y = 0,7599x + 0,1269
R = 0.7535**
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s. A. Venn diagrams represent the number of signiﬁcantly (Pb0.05) upregulated or down-
to ATRA treatment and the number of signiﬁcantly regulated genes in common (overlap).
h. RNA was extracted and hybridized on a whole mouse genome microarray. Data were
egulated genes after treatment with ATRA (Y-axis) and apo-10'-lycopenoic acid (X-axis)
associated P-value were calculated with SPSS 17. C. A heatmap was constructed for these
pacts adipose tissue biology via the retinoic acid receptors, Biochim.
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Table 1t1:1
ATRA target genes in adipose tissue and/or adipocytes.
t1:2
t1:3 Gene name Refseq number Regulation Fold change Reference
t1:4 Leptin NM_010704 Down 24.75 Felipe [27]
t1:5 Resistin NM_022984 Down 1.84 Felipe[27]
t1:6 CD36 NM_007643 Up 1.54 Han [29]
t1:7 Adiponectin NM_009605 Down 1.42 Zhang [26]
t1:8 CEBPα NM_007678 Down 3.00 Mercader [30]
t1:9 RXRα NM_011305 Down 1.66 Mercader [30]
t1:10 UCP2 NM_011671 Up 3.33 Mercader [30]
t1:11 PGC1α NM_008904 Up 2.54 Mercader [30]
t1:12 PPARα NM_011144 Up 3.54 Mercader [30]
4 E. Gouranton et al. / Biochimica et Biophysica Acta xxx (2011) xxx–xxx2.10. Statistical analysis
Data are expressed as the means ± SEM. Signiﬁcant differences
between control and treated groups were determined by one-way
ANOVA, followed by Fisher's PLSD test using Statview software (SAS
Institute, Cary, NC, USA). Values of Pb0.05 were considered signiﬁcant.
3. Results
3.1. Apo-10'-lycopenoic acid modulates the transcriptome of 3T3-L1
adipocytes in a manner similar to ATRA
To study in detail the impact of apo-10-lycac (structure in Suppl.
Fig. 1), in terms of gene expression on adipocytes, we performedU
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Fig. 2. Apo-10’-lycopenoic acid has no inﬂuence on 3T3-L1 adipocyte differentiation. At
2-days post-conﬂuence, 3T3-L1 preadipocytes (day 0)were stimulated to induce differen-
tiation with 0.5 mM isobutylmethylxanthine, 0.25 μM dexamethasone, and 1 μg/ml insu-
lin, for 48 h. To examine the effect of apo-10'-lycopenoic acid on adipocyte differentiation,
2-days post-conﬂuent 3T3-L1 preadipocytes received apo-10’-lycopenoic acid (2 μM)
every 2 days or ATRA (2 μM) as a positive control until the end of the experiment at day
9. Total RNA was extracted and reverse transcribed with MMLV. Real time PCR was
performed using speciﬁc primers. 18S rRNA was used as the endogenous control. Data
are presented as means±SEM; * represents a signiﬁcant difference treated ATRA condi-
tion and control; Pb0.05. Apo-10’-lycopenoic acid is abbreviated as apo-10-lycac.
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microarray experiments. 3T3-L1 adipocytes were incubated with apo-
10-lycac (2 μM for 24 h). Since apo-10-lycac effect are supposed to be
mediated at least in part by RAR [15], 3T3-L1 were also incubated
with ATRA (2 μM for 24 h), a well-known RAR ligand. The impact of
these treatments on the transcriptome was evaluated with a fold
change ﬁlter of 1.5. As seen in Fig. 3, 5093 genes were regulated
(2,793 were upregulated and 2300 were downregulated) by ATRA
(Pb0.05) and 607 genes were regulated by apo-10-lycac (439 were
upregulated and 168 were downregulated). Remarkably, 164 genes
were upregulated or downregulated by both ATRA and apo-10-lycac
(119 were upregulated and 45 were downregulated (Fig. 1A)), i.e.,
27% of the genes regulated by apo-10-lycac were also regulated by
ATRA, which suggests a selective overlap between the two genes lists.
In addition, the fold change of genes regulated by ATRA (Y-axis) was
plotted against the fold change of genes regulated by apo-10-lycac (X-
axis; Fig. 1B). This scatter plot revealed a highly signiﬁcant (Pb0.01) lin-
ear correlation between the two treatment conditions (Pearson coefﬁ-
cient of correlation 0.7535). The heatmap established using these
ﬁltered data convincingly illustrated the strong similarity between the
two treatments in terms of their impact on gene expression (Fig. 1C).
It is noteworthy that genes previously shown to be modulated by
ATRA in adipocytes and/or adipose tissue (Table 1) were found to be
regulated [26–31], which validated our microarray experiments. In ad-
dition, pathway analysis was performed. For this analysis, we used the
list of genes regulated by apo-10-lycac and ATRA treatments. Several
pathways were signiﬁcantly regulated by the two molecules (Table 2).
Interestingly, of the pathways identiﬁed, the one called “Ligand-
dependent transcription of retinoid-target genes” (Metacore no-
menclature) was deeply affected: of the 32 genes involved in this
pathway, 21 were regulated by the treatments (Pb1.36e-04).
Taken together, these data suggested that apo-10-lycac and ATRA
shared similarities in terms of their effects on gene expression.
This was in agreement with the hypothesis of a similar action for
the same nuclear receptor.
3.2. Apo-10'-lycopenoic acid does not modulate adipogenesis in 3T3-L1 cells
Because adipogenesis, a major event in adipocyte biology, is inhib-
ited by ATRA [32], we evaluated whether apo-10-lycac was also able
to inhibit adipogenesis in a similarmanner. 3T3-L1 cellswere incubated
in the presence of apo-10-lycac (2 μM) or ATRA (2 μM) during the
differentiation process and the expression of PPARγ, C/EBPα and adipo-
nectin were evaluated as reporters for the extent of adipogenesis. As
expected,we observed an increase in the level PPARγmRNAat different
points in the differentiation process (×7.3, ×13.3 and ×16.2 at days 3, 6
and 9, respectively; Fig. 2). The same pattern of resultswas observed for
the two other genes, C/EBPα and adiponectin, demonstrating normal
differentiation of adipocytes. In contrast to ATRA, which strongly inhib-
ited the PPARγ, C/EBPα and adiponectin mRNA expression levels,
apo-10-lycac did not affect the expression of these mRNAs, which
strongly suggests that apo-10-lycac did not have an impact on adipo-
genesis in 3T3-L1 cells.
3.3. Apo-10'-lycopenoic acid reduces the production of proinﬂammatory
markers by adipose tissue and adipocytes
Low-grade inﬂammation of adipose tissue is a well-established con-
tributor to the development of obesity-associated pathologies. It has
been demonstrated that ATRA modulates inﬂammation via RAR and
NF-κB [33]. Therefore, we tested whether this property was shared
with apo-10-lycac. For this purpose, 3T3-L1 cells were incubated with
apo-10-lycac (2 μM) or ATRA (2 μM) for 24 h, followed by incubation
with TNFα (15 ng/ml) for 3 h. As expected, we observed an increase
of IL-6 (×9.7) and IL-1β (×3.7) mRNA levels after TNFα incubation.
This induction was partially reversed (IL-6 (−20%), IL-1β (−40%) and
IL-6 (−20%), IL-1β (−60%)) (Fig. 3A) when the cells were pretreatedpacts adipose tissue biology via the retinoic acid receptors, Biochim.
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Table 2t2:1
Pathways regulated by both apo-10'-lycopenoic acid and ATRA.
t2:2
t2:3 Map Map Folders P-value
t2:4 Cytoskeleton remodeling_Role of PKA in
cytoskeleton reorganization
Protein function/kinases regulatory processes/
cytoskeleton remodeling
5,77E-09
t2:5 Cytoskeleton remodeling_Cytoskeleton remodeling Congenital, hereditary, and neonatal diseases and
abnormalities regulatory processes/cytoskeleton remodeling
1,76E-07
t2:6 Development_Role of IL-8 in angiogenesis Protein function/G-proteins/GPCR regulatory processes/
development/angiogenesis
6,84E-07
t2:7 Cell adhesion_Integrin-mediated cell adhesion
and migration
Regulatory processes/cell adhesion 3,04E-06
t2:8 Transcription_Sin3 and NuRD in transcription regulation Regulatory processes/transcription 6,81E-06
t2:9 Cell adhesion_Role of tetraspanins in the integrin-mediated
cell adhesion
Regulatory processes/cell adhesion 1,45E-05
t2:10 Cytoskeleton remodeling_Integrin outside-in signaling Regulatory processes/cell adhesion regulatory processes/
cytoskeleton remodeling
2,28E-05
t2:11 Transport_Clathrin-coated vesicle cycle Disease maps/lung diseases/cystic ﬁbrosis regulatory
processes/Transport
2,32E-05
t2:12 Cell adhesion_Integrin inside-out signaling Regulatory processes/cell adhesion 2,45E-05
t2:13 Cell adhesion_Endothelial cell contacts by
non-junctional mechanisms
Regulatory processes/cell adhesion 2,66E-05
t2:14 Cytoskeleton remodeling_Fibronectin-binding
integrins in cell motility
Regulatory processes/cell adhesion regulatory processes/
cytoskeleton remodeling
3,08E-05
t2:15 Cell adhesion_Chemokines and adhesion Congenital, hereditary, and neonatal diseases and abnormalities
protein function/cyto/chemokines Regulatory processes/Cell adhesion
4,86E-05
t2:16 Cytoskeleton remodeling_Regulation of actin
cytoskeleton by Rho GTPases
Protein function/G-proteins/RAS-group Regulatory processes/
cytoskeleton remodeling
6,19E-05
t2:17 Regulation of CFTR activity (norm and CF) Congenital, hereditary, and neonatal diseases and abnormalities
disease maps/lung diseases/cystic ﬁbrosis
1,04E-04
t2:18 Transcription_Ligand-Dependent Transcription of
Retinoid-Target genes
Protein function/transcription factors 1,37E-04
t2:19 Cytoskeleton remodeling_TGF, WNT and
cytoskeletal remodeling
Congenital, hereditary, and neonatal diseases and abnormalities
regulatory processes/cytoskeleton remodeling
2,05E-04
t2:20 Cell adhesion_Histamine H1 receptor signaling
in the interruption of cell barrier integrity
Protein function/G-proteins/GPCR Regulatory processes/Cell adhesion 2,22E-04
t2:21 Apoptosis and survival_BAD phosphorylation Regulatory processes/Apoptosis and survival 2,41E-04
t2:22 Neurophysiological process_Receptor-mediated
axon growth repulsion
Congenital, hereditary, and neonatal diseases and abnormalities
regulatory processes/cell adhesion regulatory processes/cytoskeleton
remodeling regulatory processes/development/neurogenesis regulatory
processes/neurophysiological process
2,81E-04
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Cwith apo-10-lycac and ATRA respectively. These effects were conﬁrmed
in two additionalmodels in the case of apo-10-lycac. Inguinal adipose tis-
sue explants of mice fed a high-fat diet were incubated ex vivowith apo-
10-lycac (2 μM) for 24 h. We observed an important decrease of IL-6
(−58%) and IL-1β (−82%) mRNA levels in explants that were incubated
in the presence of apo-10-lycac compared to the control (Fig. 3A).We also
used human primo cultures. Cells were incubated with apo-10-lycac
(2 μM) for 24 h, followed by incubation with TNFα (15 ng/ml) for 3 h.
As expected, we observed an increase of IL-6 (×16.7) and IL-1β (×17.2)
mRNA levels after TNFα incubation. This inductionwas partially reversed
(IL-6 (−20%) and IL-1β (−30%)) (Fig. 3B)when the cellswerepretreated
with apo-10-lycac treatment. Taken together, these data strongly suggest
that apo-10-lycac and ATRA exert anti-inﬂammatory effects in adipose
tissue and adipocytes.
3.4. Apo-10'-lycopenoic acid transactivates RAR in vivo, in vitro and
modulates the transcription of RAR target genes in mouse adipose tissue
We took advantage of the RARE-luciferase mouse model [19], in
order to examine the ability of apo-10-lycac to transactivate RAR in
vivo, in adipose tissue. As expected, we observed a strong induction of
the luciferase reporter in white adipose tissue (WAT; Fig. 4A). This abil-
ity of apo-10-lycac to transactivate RAR was conﬁrmed in vitro in
3T3-L1 cells (Fig. 4B). The maximum transactivation (about 25%) of
RAR for apo-10-lycacwas obtained for the 2 μMconcentration,whereas
ATRA signiﬁcantly induced RAR transactivation for lower concentration
(1 μM).
In addition, we evaluated the induction of CYP26A1 and RARβ
(Fig. 4C), two well-known RAR target genes in adipose tissue [34].
Upon ATRA and apo-10-lycac treatment, these genes were stronglyPlease cite this article as: E. Gouranton, et al., Apo-10'-lycopenoic acid im
Biophys. Acta (2011), doi:10.1016/j.bbalip.2011.09.002induced (82 and 10 fold induction respectively for CYP26A1; 1.8 and
2.3 fold induction respectively for RARβ). Interestingly, apo-10-lycac
signiﬁcantly induced (Pb0.05) the reporter gene expression in the
lung and intestine, while transactivationwas not observed in other test-
ed organs (Suppl. Fig. 2). Therefore, apo-10-lycac seems to be an activa-
tor of RAR in speciﬁc organs, suggesting that an organ speciﬁc
environment is needed for apo-10'-lycopenoic acid transactivation of
RAR-signaling.
To conﬁrm the regulation of several other ATRA target genes by
apo-10-lycac in adipose tissue, we evaluated the mRNA level of a
panel of genes, chosen from Table 1 that were regulated in the same
manner by both ATRA and apo-10-lycac in microarray experiments.
Therefore, validation was conducted for PPARα, RXRα, leptin and
CEBPα. As shown in Fig. 5, we observed a downregulation of leptin,
CEBPα and RXRα and an upregulation for PPARα, conﬁrming thus in
vivo the microarray data. Together, these data supported the effect of
apo-10-lycac on the expression of known ATRA target genes in vivo.
3.5. Apo-10'-lycopenoic acid is not present in human adipocytes and
mouse adipose tissue
To detect apo-10-lycac in tissues or cells, we used an HPLC MS-MS
approach. With a protocol analysis speciﬁcally primed for apo-10-
lycac using MRM conditions with 393→269 m/z, a small peak was
detected only in the spleen of mice that were treated intravenously
with lycopene (Fig. 6A). Based on these weak criteria we just can spec-
ulate that apo-10-lycac is an endogenous metabolite of lycopene in
mice. In addition, potential cis-isomers of apo-10-lycac are indicated
by the box in scattered lines in Fig. 6A. In the white adipose tissue
(WAT) of mice orally treated with vehicle control, lycopene or apo-pacts adipose tissue biology via the retinoic acid receptors, Biochim.
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Fig. 3. Apo-10'-lycopenoic acid decreases inﬂammation in 3T3-L1 cells, in adipose tissue explants of mice subjected to HFD in ex vivo culture and in primo culture of human mature
adipocytes in vitro. A. 3T3-L1 adipocytes were incubated with apo-10’-lycopenoic acid (2 μM) or ATRA (2 μM) for 24 h and then incubated with TNFα (15 ng/ml) for 3 h. B. Adipose
tissue of mice force fed with a high-fat diet for 6 weeks was recovered and incubated with apo-10’-lycopenoic acid (2 μM) for 24 h C. Human adipocytes were incubated with apo-
10’-lycopenoic acid (2 μM) for 24 h and then incubated with TNFα (15 ng/ml) for 3 h. RNAs were extracted and reverse transcribed with MMLV. Real time RT-PCR was performed
using speciﬁc primers. 18S rRNA was used as the endogenous control. Data are presented as means±SEM; Bars not sharing the same letter were signiﬁcantly different, Pb0.05.
Apo-10'-lycopenoic acid is abbreviated as apo-10-lycac.
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10-lycac, no peak that co-elutedwith apo-10-lycacwas observed. In ad-
dition, no compound with a co-elution of apo-10-lycac was found in
human cultured adipocytes with/without lycopene treatment (Fig. 6B)
which indicates a quick and completely metabolism of apo-10-lycac in
WAT. However, with the mass spectrometer in a single ion recording
(SIR) conﬁguration set at 395 m/z, which represents apo-10-lycac plus
2 Da, we detected a peak that has a retention time that is slightly longer
than apo-10-lycac. This peak strongly increased in mouseWAT after ly-
copene and apo-10-lycac treatment in comparisonwith vehicle-treated
animals (Fig. 6C). This suggests that a dihydro-apo-10'-lycopenoic acid
was present within adipose tissue and could be an endogenous
derivative, as well as a nutritionally relevant lycopene metabolite. The
exact chemical structure of this dihydro-apo-10'-lycopenoic acid
compounds still remained elusive because of nine different positions
of hydrogenation and isomerisation of various conjugated double
bounds. Exact chemical identiﬁcation using MS-MS examination was
impossible yet because of low endogenous concentrations of this
dihydro-apo-10'-lycopenoic acid. One additional information that we
obtained is the UV spectra of this dihydro-apo-10'-lycopenoic acid
with an UVmax of 398 nm (Fig. 6D), this UVmax indicated that we
may have six conjugated double bounds and an additional conjugated
COOH-group [17]. As a reference we had apo-14'-lycopenoic acid with
six conjugated double bounds and an additional conjugated COOH-
group with an UVmax of 399 nm [17]. Thereby we postulated that
7,8-dihydro-apo-10'-lycopenoic acid might be the novel endogenous
and nutritional relevant lycopene/apo-10'-lycopenoic acid metabolite
(Fig. 6E). Further investigation using an organic-synthetic approach isPlease cite this article as: E. Gouranton, et al., Apo-10'-lycopenoic acid im
Biophys. Acta (2011), doi:10.1016/j.bbalip.2011.09.002needed to conclusively determine the exact chemical structure of this
potential metabolite of lycopene.
4. Discussion
In the present study, we report for the ﬁrst time the effects of apo-
10'-lycopenoic acid (apo-10-lycac), a putative human and mouse
metabolite of lycopene, on adipose tissue/adipocytes. These data
strengthen the role of lycopene and/or metabolites on adipose tissue
and adipocytes [1,5,6].
Firstly, we determined the impact of apo-10-lycac on gene expres-
sion in adipose tissue, we performed microarrays experiments. The
effect of apo-10-lycac was compared to ATRA, a classical RAR ligand.
We used adipocytes as a model because they make up the main cellu-
lar population of adipose tissue. Apo-10-lycac and ATRA were found
to induce highly similar gene expression proﬁles. Several classical
ATRA target genes in adipose tissue/adipocytes were found to be reg-
ulated under our conditions, validating our microarray results.
Furthermore, several target genes of apo-10-lycac treatments in
vitro were shown to be regulated in a mouse model, which reinforces
the physiological relevance of the results obtained in vitro.
It is noteworthy that genes are more differentially affected by
ATRA than by apo-10-lycac, in terms of fold change in expression, as
reﬂected by the slope of the correlation line (Fig. 1B). Such a discrep-
ancy might be due to the lower efﬁciency of apo-10-lycac to transac-
tivate RAR as compared to ATRA (Fig. 4B) as well as effects of ATRA on
gene expression via non-genomic mechanisms that may not bepacts adipose tissue biology via the retinoic acid receptors, Biochim.
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Fig. 4. Apo-10'-lycopenoic acid transactivates RAR in vivo, in vitro and induces CYP26A1 and RARβ in adipose tissue ofmice in vivo. A. Ten- to twelve-week-old RARE-lucmice, engineered
to express ﬁreﬂy luciferase gene under the control of RARE, were treatedwith apo-10’-lycopenoic acid (4 mg/kg bodyweight; apo-10’-lycac), ATRA (50 mg/kg bodyweight) or DMSO by
oral gavage 16 h before screening. Fifteenminutes after luciferin injection, white adipose tissue (WAT) and lungs were rapidly excised and placed in a tight light chamber for biolumines-
cence screening. Luciferase expression is expressed as integrated intensity/area. B. Mice were force fed apo-10'-lycopenoic acid (4 mg/kg body weight). Epididymal adipose tissue was
recovered 16 h later. Total RNA was extracted and reverse transcribed using MMLV. Real time RT-PCRwas performed using speciﬁc primers. 18S rRNA was used as the endogenous con-
trol. Means±SEM are shown; values for 4–6 different animals per treatment group are shown. C. 3T3-L1 cells were transiently transfected with plasmids coding for Gal4-RAR and TK-
MH100x4-Luc. Cells were treated for 24 h with various concentrations of apo-10-lycac or ATRA. The β-galactosidase and luciferase dosages were performed as described in Materials
and Method section. Bars not sharing the same letter were signiﬁcantly different, Pb0.05.; Apo-10'-lycopenoic acid is abbreviated as apo-10-lycac.
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Cshared with apo-10-lycac. Indeed, ATRA has been reported to impactseveral signaling pathways, including protein kinases, p38MAPK andErk1/2 [35–37]. Currently, similar effects have not been reported for
apo-10-lycac. Conversely, apo-10-lycac-treatment regulated genes
were not regulated by ATRA. This might be due to the ability of apo-
10-lycac-treatment to activate the transcription factor Nrf2 [14].U
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Fig. 5. Expression of leptin, RXRα, PPARα and C/EBPα in the adipose tissue of mice in response
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Please cite this article as: E. Gouranton, et al., Apo-10'-lycopenoic acid im
Biophys. Acta (2011), doi:10.1016/j.bbalip.2011.09.002Currently, the effect of ATRA on the activation of Nrf2 remains unclear
because the literature reports both activation [38] and inhibition [39].
Pathway analysis revealed a common pattern of effects, especially
a common impact on the retinoid target gene transcription. This im-
plies that both apo-10-lycac and ATRA directly or indirectly regulate
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Fig. 6. Apo-10'-lycopenoic acid is not present in adipose tissue frommice treatedwith lycopene or apo-10’-lycopenoic acid aswell as in human adipose tissue treatedwith lycopene, but a
related compound dihydro-apo-10'-lycopenoic acid may be present. A. Male mice were treated intravenously with an aqueous lycopene-beadlet solution (50 mg/kg body weight). In
vehicle treated animals, no peak was present and the data are not shown here. Using HPLC MS-MS with apo-10'-lycopenoic acid primed MRM settings we observed a peak in the
spleen, which co-eluted with apo-10'-lycopenoic acid (marked by the scattered line), and small peaks, which co-eluted before and may correspond to potential geometric isomers of
apo-10’-lycopenoic acid (marked by the scattered line box). In other tissues of lycopene-treated animals, such as serum, WAT, testis and liver, no co-eluting peak was observed. B.
RARE-reporter mice with lycopene or apo-10'-lycopenoic acid treatment with up-regulated RARE activity and human adipocytes treated with/without lycopene were analyzed by
HPLC MS-MS with apo-10’-lycopenoic acid primed MRM settings. C. RARE reporter mice with lycopene or apo-10’-lycopenoic acid treatment induced up-regulation of RARE activity
were analyzed by HPLC MS-MS with SIR settings for 395 m/z. D. UV spectra of the peak with the MS of apo-10'-lycopenoic acid+2 Da (see Fig. 6C). E. 7,8-dihydro-apo-10'-lycopenoic
acid as a proposed chemical structure as an apo-10'-lycopenoic acid/lycopene-metabolite including a comparable structure of apo-14'-lycopenoic acid, a derivative with 6 conjugated
double bounds. Apo-10'-lycopenoic acid is abbreviated as apo-10-lycac, lycopene as LYC, and control as CTRL.
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RAR target gene. In addition, we have demonstrated that apo-10-
lycac transactivates RAR in adipose tissue in vivo and in vitro in adipo-
cytes. Such a transactivational effect was suspected from in vitro data
in lung [15]; however, we report here, for the ﬁrst time an in vivo ef-
fect as well as an effect in vitro in adipocytes. Interestingly, both mol-
ecules could have a strong impact on the transcription of retinoid
target genes, not only via activation of RAR, but also via the induction
of the transcription of several genes involved in this pathway.
Due to the large shape of apo-10-lycopenoic acid we do not expect
a direct interaction with the RARs and postulate further smaller
downstreammetabolites which may directly bind and directly initiat-
ed RAR-mediated signaling. Unfortunately these ligands are expected
to be present in ultra-low endogenous concentrations comparable
like retinoic acids [40] even after apo-10'-lycopenoic acid or lycopene
treatments. Studies about the existence, endogenous presence and
structure of direct RAR-interacting lycopene-metabolites are current-
ly under investigation in our laboratories.
Based on these effects of apo-10-lycac on adipose tissue/adipocyte
gene transcription via RAR, we sought to evaluate the impact of this
molecule on two physiological processes that occur in adipose tissue
and are directly related to physiopathological disorders. Therefore, we
studied the effect of apo-10-lycac on adipogenesis and adipose tissue/Please cite this article as: E. Gouranton, et al., Apo-10'-lycopenoic acid im
Biophys. Acta (2011), doi:10.1016/j.bbalip.2011.09.002adipocyte inﬂammation because ATRA has displayed some effects on
these processes, notably through RAR [31–33]. Adipogenesis is related
to the process of hyperplasia within adipose tissue. Unlike ATRA,
which is a well-known inhibitor of adipogenesis at high concentration
[32], apo-10-lycac treatments had no effect on adipogenesis under
these conditions. This lack of effect of apo-10-lycac at this concentration
(2 μM) could be due to its weaker activity (as shown in microarrays
experiments and in transactivation experiments; Figs. 1B and 4B) as
compared to ATRA. This point is particularly important to underline,
since at low concentration ATRA display inverse effect on adipogenesis.
Thus apo-10-lycac could present similar effects of a low concentration
of ATRA. If we consider that adipogenesis, and particularly adipogenesis
in subcutaneous adipose tissue, is a beneﬁcial process thatmight partic-
ipate to limit the prevalence of obesity-related pathologies [41], the lack
of negative effects of apo-10-lycac treatment on adipogenesis may be
considered beneﬁcial, however the origin of this discrepancy between
apo-10-lycac and ATRA on adipogenesis would require further
investigations.
In addition, we demonstrated that apo-10-lycac was able to modu-
late inﬂammation in adipose tissue and adipocytes. This process is
also deeply involved in the genesis of obesity-related pathologies,
such as insulin resistance, where inﬂammatory markers are known topacts adipose tissue biology via the retinoic acid receptors, Biochim.
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have a strong negative impact [42–44]. Therefore, by showing that
apo-10-lycac could reduce the expression of some proinﬂammatory
markers, we can hypothesize that this molecule has a beneﬁcial effect
on inﬂammation-related pathologies, such as insulin resistance, like
lycopene [6]. Such an effect is probably due to the reduction of NF-κB
activity that is mediated by the retinoic acid receptor, as previously
reported [6,33]. These data support a beneﬁcial role of apo-10-lycac in
the prevention of obesity-related pathologies; however, additional
experiments are required to demonstrate this in vivo.
Weﬁnallywanted to determine in this studywhether apo-10-lycac or
related derivatives are present in tissues. The presence of apo-10-lycac
was partially conﬁrmed in mouse spleen after intravenous injection, this
co-elution is just a weak criteria but full identiﬁcation usingMS-MS tech-
niques is not possible due to very low concentration of this derivative in
the spleen. However, apo-10-lycac was not present in adipose tissue or
human adipocytes following a regimen or incubation with lycopene or
apo-10-lycac. Interestingly, we found a derivative with a mass of
apo-10-lycac plus 2 Da using a highly sensitive HPLC MS-MS analysis.
This ﬁnding suggests that one of the eight conjugated double bonds is
hydrogenated; supporting the hypothesis that apo-10-lycac is quickly
and completely metabolized in adipose tissue and adipocytes. Using an
UV detector we additionally found out that six double bounds plus an
additional conjugated COOH-group may be present and lets us propose
that this compound is 7,8-diyhdro-apo-10'-lycopenoic acid. Such a com-
pound could be produced by Retsat which is able to metabolize retinoic
acid to dihydroretinoic acid [45], but so far, we cannot conclusively deter-
mine that this metabolite is in ﬁne the active derivative of apo-10-lycac.
Due to the complex structure and potential geometric isomers of this
potential novel derivative, this peak could not be conclusively identiﬁed
in this study. Studies to completely identify this novel lycopene metabo-
lite, including its biological activity, are ongoing.
To conclude, in the present study, we show that In adipocytes,
apo-10-lycac treatment exhibits important similarities with ATRA in
terms of gene regulation. Consistently we reported that apo-10-lycac
treatments can initiate transactivation of RAR in a transgenic reporter
animal model, and induce the expression of several RAR target genes.
Moreover, it possesses anti-inﬂammatory properties in adipose tissue
and adipocyte models, but it does not have an effect on adipogenesis.
While this compound was not found in adipose tissue/adipocytes, we
identiﬁed a dihydro-metabolite of apo-10-lycac with a proposed struc-
ture of 7,8-dihydro-apo-10'-lycopenoic acid that will require further
study. Thus, apo-10-lycac treatment and its further metabolites may
be considered as potentially relevant compound in the context of obesi-
ty/diabetes prevention.
Supplementary materials related to this article can be found online
at doi:10.1016/j.bbalip.2011.09.002.
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